New drug combo aims to shrink tough stomach cancers

NCT ID NCT06846346

Recruiting now Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding the immunotherapy drug ivonescimab to standard chemotherapy can improve tumor shrinkage in people with advanced or metastatic stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is to see if more patients respond to the combination compared to chemo alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab (a type of immunotherapy) combined with chemotherapy drugs (FOLFOX or irinotecan)
What this could lead to: If successful, this could lead to a new treatment option that shrinks tumors more effectively in people with advanced stomach or esophageal cancer.
What could go wrong: This is an early Phase 2 trial with only 88 participants, so results may not apply to everyone. The combination may cause side effects or not work better than chemo alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED ESOPHAGEAL ADENOCARCINOMA ADVANCED GASTRIC ADENOCARCINOMA METASTATIC ESOPHAGEAL ADENOCARCINOMA METASTATIC GASTRIC ADENOCARCINOMA

Contacts and locations

Locations

Centre Léon Bérard
RECRUITING

Lyon, 69008, France
Institut Jean Godinot
RECRUITING

Reims, 51100, France
Institut Paoli Calmettes
NOT_YET_RECRUITING

Marseille, France
Institut de Cancerologie de l'Ouest - Site René Gauducheau
NOT_YET_RECRUITING

Saint-Herblain, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.